1,401 results on '"Reich, Adam"'
Search Results
102. Perceived Stigmatization among Dermatological Outpatients Compared with Controls: An Observational Multicentre Study in 17 European Countries
103. Psoriasis
104. Cutaneous Drug Reactions and Drug-Induced Pruritus
105. Clinical and epidemiological analysis of basosquamous carcinoma: results of the multicenter study
106. How 'Nothing Works' Was Won: The End of Treatment and Fracturing of the Asylum
107. From Hard Labor to Market Discipline: The Political Economy of Prison Work, 1974 to 2022.
108. Polish guidelines for the diagnosis and treatment of hidradenitis suppurativa.
109. White paper on psychodermatology in Europe: A position paper from the EADV Psychodermatology Task Force and the European Society for Dermatology and Psychiatry (ESDaP).
110. IFSI-guideline on chronic prurigo including prurigo nodularis
111. Pruritus
112. Trichotillomania and Trichophagia: Modern Diagnostic and Therapeutic Methods
113. Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
114. Skin Microbiome in Prurigo Nodularis
115. How does a chronic wound change a patient's social life? A European survey on social support and social participation
116. walmart’s consumer redlining
117. Selling Our Souls: The Commodification of Hospital Care in the United States
118. Working for Respect
119. Chłoniaki pierwotne skóry. Rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego (PTD) i Polskiej Grupy Badawczej Chłoniaków (PLRG).
120. Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies.
121. Chronic prurigo: Insufficient disease control in spite of high healthcare usage
122. Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland
123. Skin pain: A symptom to be investigated
124. 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay
125. 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis
126. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
127. Characteristics of pruritus in various clinical variants of psoriasis: Final report of the binational, multicentre, cross‐sectional study
128. Primary cutaneous lymphomas. Diagnostic and therapeutic guidelines of the Polish Dermatological Society (PTD) and Polish Lymphoma Research Group (PLRG)
129. Hailey-Hailey disease exacerbated by scabies: the role of dermatoscopy in preventing misdiagnosis
130. A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021
131. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
132. Workers' Health On the Line: A Digital Intervention to Address the Fundamental Causes of Disease in the Low-Wage Retail Sector
133. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
134. Biologics for Itch: IL-4/IL-13, IL-31, IL-17, and IL-23 Antagonists
135. Inherited ichthyoses patients: Individualized care and support urgently needed.
136. Tolerance and efficacy of a spray containing Rhealba oat plantlets and Uncaria tomentosa extracts in reducing symptoms of herpes zoster
137. Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study
138. The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum
139. Sexual Dysfunction in Women and Men with Psoriasis: A Cross-Sectional Questionnaire-Based Study
140. The Impact of Pruritus on the Quality of Life and Sleep Disturbances in Patients Suffering from Different Clinical Variants of Psoriasis
141. ESDR110 - Characteristics and management of generalized pustular psoriasis (GPP): experience from the Central and Eastern Europe (CEE) GPP Expert Network
142. Reakcja fototoksyczna po zastosowaniu diklofenaku sodowego
143. Rozlana melanoza skórna
144. 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)
145. 32240 Baseline characteristics and comorbid conditions in patients with moderate-to-severe plaque psoriasis enrolled in the Psoriasis Study of Health Outcomes (PSoHO)
146. 33307 Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis
147. Drugs
148. Inflammatory Diseases
149. Chapter 21 - Skin manifestations and autoimmune disturbances in dermatomyositis
150. 53111 Individual patient responses to IL-22RA1 inhibition in a Phase 2a monotherapy trial for moderate-to-severe atopic dermatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.